Previously, we and others have demonstrated in several animal models that the establishment of stable haematopoietic chimerism through allogeneic bone marrow transfusion provides an effective means for the development of specific transplantation tolerance. However, a major limitation to the clinical application of allogeneic bone marrow transfusion in immunosuppressed recipients for induction of tolerance to solid grafts, is the risk of graft-versus-host disease (GVHD). Therefore, it is important to identify the cell population needed for the induction of mixed chimerism and tolerance. Haematopoietic stem cells have the capacity of self-renewal and multilineage differentiation, and have been shown to reduce the risk of GVHD. We studied transfusion of two rich sources of stem cells, namely allogeneic fetal liver cells and a subset of purified bone marrow-derived progenitor cells (c-kit + ) into anti-T cell monoclonal antibody-treated, low-dose irradiated recipient mice. Our data revealed that stable multilineage mixed chimerism and permanent donor-specific tolerance for skin, even when transplanted directly following conditioning, can be successfully achieved in this way, with no signs of GVHD.
create a state of mixed lymphohaematopoietic chimerism rather than full donor reconstitution. Moreover, mixed chimeras are relatively resistant to GVHD.
In the adult recipient, different strategies have been developed to achieve stable mixed chimerism across MHC barriers. In these trials, nonlethal TBI, [4] [5] [6] [7] total lymphoid irradiation (TLI), 8 thymic irradiation (TI), 9 cyclophosphamide (CY) 10 or dimethyl myleran (DMM) 11 was utilized as part of the preparative regimen to enable establishment of mixed chimerism. These procedures, however, are inapplicable in clinical transplantation using cadaveric donors due to the relatively long-time interval between the start of tolerance induction and the actual organ transplantation, or to the extremely high dose of donor bone marrow cells needed. 9 The single-day protocol we have developed for induction of mixed chimerism in a fully allogeneic murine model, involves a single dose of anti-CD3 and anti-CD4, low-dose TBI (3-6 Gy), and administration of allogeneic bone marrow cells. [12] [13] [14] Skin transplantation was performed within 1 h following conditioning. With this nonlethal conditioning regimen stable, multilineage mixed chimerism and permanent acceptance of donor-specific skin grafts was achieved. 14 To reduce the risk for GVHD in the clinical situation, the present study deals with the use of haematopoietic stem cells to achieve engraftment across allogeneic barriers. Previously, it has been reported that both syngeneic and allogeneic fetal liver cells are able to restore haematopoiesis and lymphopoiesis in lethally irradiated animals, without inducing overt GVHD. 15, 16 These findings, together with the evidence of the presence of pluripotent haematopoietic stem cells in the mammalian fetal liver, 17, 18 prompted us to investigate reconstitution with stem cell-enriched populations in our nonlethal transplantation model.
Murine pluripotent haematopoietic stem cells and progenitor cells express c-kit, 19 a receptor for stem cell factor. Upon maturation from lineage neg to lineage pos bone marrow cells, the expression of c-kit gradually decreased. Flow cytometric analysis revealed that fetal liver tissue contains a higher percentage of c-kit + cells (Ϯ20%) than adult bone marrow (Ϯ10%) (not shown). We now report for the first time that purified adult bone marrow-derived c-kit + cells can be used in our nonlethal, single-day, fully allogeneic skin transplantation model. Our data demonstrate that the use of MHC-disparate stem cells results in the induction of stable multilineage mixed chimerism and permanent donorspecific tolerance, without evidence of GVHD. 
Materials and methods

Animals
Monoclonal antibodies
For immunosuppression of the host, anti-CD3 (145-2C11; generously provided by Dr JA Bluestone, University of Chicago, Chicago, IL, USA) and anti-CD4 (GK1.5; American Type Culture Collection, Rockville, MD, USA) monoclonal antibodies were used as previously reported. 12 
Preparation of cell suspensions
Using sterile procedures, fetal livers were dissected from 15 to 18 day old fetuses, and pooled. With gentle disruption, a single cell suspension was prepared. Erythrocytes were lysed with an ammonium chloride buffer. Recipient animals were reconstituted with 5-10 ϫ 10 6 allogeneic fetal liver cells in 0.25 ml of saline containing 5% heat-inactivated autologous serum via caudal vein injection. Bone marrow cells were obtained by flushing femoral and tibial bones from donor mice with Iscove's modified Dulbecco's medium supplemented with 10% heat-inactivated FCS. After lysis of eythrocytes, the bone marrow cell suspension was incubated with FITC-conjugated anti-c-kit (2B8; Pharmingen, San Diego, CA, USA) monoclonal antibody for 30 min at 4°C. C-kit + cell populations were positively selected using live sterile cell sorting (FACStar Plus; Becton Dickinson, Mountain View, CA, USA). Cells isolated by this approach represent approximately 10% of the original bone marrow population. Although we measured a higher level of c-kit + cells in fetal liver tissue (approximately 20%), we used, for clinical relevance, bone marrow-derived c-kit + cells in our model. After collection, 1-2.5 ϫ 10 6 isolated bone marrow-derived c-kit + cells were resuspended and injected into conditioned mice in a total volume of 0.25 ml saline supplemented with 5% autologous serum.
Conditioning regimen
Chimeras were prepared with modifications of the previously described nonlethal regimen. 12, 13 Briefly, B10 mice were treated with 3-6 Gy TBI. Three to four hours later, irradiated mice received a single dose of 400 g anti-CD3 i.p. and 5-10 ϫ 10 6 fully mismatched B10.D2 or haploidentical (B10 x B10.D2)F1 fetal liver cells or 1-2.5 ϫ 10 6 c-kit + B10.D2 bone marrow cells i.v. Just prior to conditioning, recipient mice were given 500 g anti-CD4, in order to reduce the contribution of CD4-positive T cells to the 'cytokine release syndrome', associated with anti-CD3 treatment. 12 
Skin transplantation
Within 1 h or 7 weeks after completing the conditioning regimen, tail skin transplantation was performed. Each recipient mouse was given a control B10 (syngeneic), a B10.D2 or (B10 × B10.D2)F1 (donor) and a B10.BR (third party) skin graft. The grafts were inspected three times a week and considered to be rejected when no viable donor skin was detectable. Second donor-type skin grafts were transplanted 4 months after the first skin grafts.
Flow cytometric analysis
Engraftment of donor cells was evaluated by two-color flow cytometric analysis of peripheral blood cells (PB), mesenteric lymph node cells (LN) and splenocytes using a FACScan (Becton Dickinson). All procedures were performed in PBS containing 0.2% bovine serum albumin and 0.05% sodium azide. Fluorescence data were collected by using logarithmic amplification on 10 4 viable cells as determined by forward light scatter intensity. To quantify chimerism, two-color staining with H-2D 
Cell-mediated lympholysis (CML)
CML assays were performed as described previously. 
Results
Allogeneic fetal liver cells induce specific allograft tolerance
Recipient mice were treated with anti-CD3 and anti-CD4 monoclonal antibodies, low-dose total body irradiation (TBI) (3-6 Gy) and i.v. injection of fully allogeneic or semi-allogeneic fetal liver cells. First, we investigated the haematopoietic reconstitution after conditioning. This was assessed by flow cytometric analysis, 4 months after reconstitution. Table 1 shows the results of animals treated with 3-6 Gy TBI and 5-10 ϫ 10 6 fully (Table 1A) or semi-allogeneic (Table 1B) fetal liver cells. In almost all mice engraftment of donor cells has occurred.
Furthermore, we clearly found evidence for multilineage mixed chimerism. Peripheral blood, lymph nodes and spleen samples of all chimeric animals contained cells of both host and donor origin within lymphoid (T and B cells) and myeloid (granulocytes and macrophages) lineages (Figure 1 ). Donor-specific tolerance and immunocompetence in vitro were demonstrated using cellular cytotoxicity (CML) assays. Figure 2 shows that lymphocytes from stable mixed chimeras even 1.5 year after reconstitution were unresponsive against host and donor alloantigens (mutual tolerance) but were immunocompetent because they showed immune reactivity against third party target cells like control mice. Control untreated animals as well as similarly treated recipients without detectable levels of chimerism were reactive to both donor and third party alloantigens.
Most importantly, animals were tested for evidence of donor-specific tolerance in vivo by skin grafting. Only 1 h following reconstitution, animals received skin grafts of recipient, donor and third party origin. All stable mixed chimeras accepted first (transplanted directly following conditioning) and second (transplanted 4 months after the first) donor-and host-type skin grafts indefinitely, but rejected unrelated third party skin grafts (Table 1) . Rejection of first set third party skin grafts was somewhat delayed (a mean survival time of 71.5 days in mixed chimeras (n = 13) vs 27.5 days in untreated control mice (n = 2)) due to the immunosuppression shortly after conditioning. However, results after the second unrelated transplantation were comparable with that of untreated control mice (a mean survival time of 24.5 days in both chimeric and untreated animals).
Moreover, when the first skin transplantation was not performed directly, but 7 weeks after conditioning with 10 ϫ 10 6 fully allogeneic fetal liver cells, anti-T cell mAbs and 4-6 Gy TBI (stable mixed chimerism was present in nine out of 10 conditioned animals), third party grafts were rejected within 28 days (Table 2) . Again, all chimeric recipients showed permanent survival of first and second donor-and host-type skin grafts. 20 Thus, within a short time after conditioning, chimeric mice are fully reactive to third party antigens and the induced tolerance is really donorspecific.
Allogeneic purified c-kit + haematopoietic progenitor cells induce specific allograft acceptance
To determine engraftment and the repopulating ability of fully allogeneic c-kit + haematopoietic progenitor cells in our transplantation model, FACS-sorted bone marrowderived c-kit + cells of B10.D2 mice were injected into nonlethally conditioned B10 recipient mice. As shown in Figure 3 , injection of 2.5 ϫ 10 6 fully allogeneic (across full MHC barriers) c-kit + cells led to high levels of permanent stable mixed chimerism (79.9% donor-type cells 4 months after conditioning). Furthermore, we observed that even a lower dose of 1 ϫ 10 6 fully allogeneic c-kit + cells is sufficient for induction of mixed chimerism (12.0% donor-type cells). As expected, after the successful engraftment of donor-derived cells, multilineage reconstitution had occurred. Donor-type cells were observed in both the lymphoid and myeloid cell compartments (data not shown).
Transplantation of donor-and host-type skin grafts, performed directly as well as 7 weeks following conditioning (first) and 4 months after the first transplantation (second) Cr-labeled host, donor and third party targets by splenocytes from B10, B10.D2 and a representative chimera, prepared using 6 Gy TBI and 10 × 10 6 B10.D2 fetal liver cells (98.0% donor-type splenocytes). CTL response was examined 8 months after conditioning. Spontaneous release was Ͻ25%. ) was always 95-100%. c First transplantation (Tx) of host, donor and third party (B10.BR) skin grafts was performed 7 weeks following conditioning. Second skin transplantation was performed 4 months after the first. Syngeneic skin graft survival was 100%. resulted in specific graft acceptance for over 120 days. MHC-disparate third party skin grafts were always rejected.
Discussion
The transplantation of human bone marrow, peripheral blood and cord blood cells is playing an increasingly important role in the medical treatment of various malignant haematologic diseases. Haematopoietic stem cells represent the most primitive cells that establish a fully selfrenewing population and retain multilineage lymphopoietic and haemopoietic differentation potentials. Unlike bone marrow cells, stem cell-enriched populations do not contain mature lymphocytes capable of inducing GVHD. Previously, we have demonstrated that transfusion of allogeneic bone marrow cells can be used to prevent rejection of donor-specific skin grafts in partially irradiated mice. 12, 13 Stable multilineage mixed chimerism and permanent transplantation tolerance has been developed. In the present report, we investigated transfusion with two different stem cell-enriched populations, for prevention of GVHD in the clinical situation. Results show that MHC-disparate fetal liver cells as well as purified bone marrow-derived c-kit + cells can be used for induction of stable multilineage mixed chimerism and permanent acceptance of donor-specific first and second skin grafts, without any clinical signs of GVHD. Although in both situations an equivalent number of ckit + cells was injected (5-10 ϫ 10 6 fetal liver cells contain about 1-2 ϫ 10 6 c-kit + cells (20%)), the composition of this cell population is not identical. There may be differences in stem cell subsets or other cell lineages with regulatory functions (eg 'veto' cells 21 or 'facilitating' cells 22 ). Our data demonstrate, for the first time, that injection of 1-2.5 ϫ 10 6 bone marrow-derived c-kit + cells into lowdose irradiated recipients resulted in induction of mixed chimerism and transplantation tolerance across full MHC barriers. Failure of engraftment was observed after injection of 0.5 ϫ 10 6 c-kit + cells. Engraftment and function of allogeneic stem cells is a complex process because of several immunological and physiological obstacles. Low numbers of highly purified stem cells, eg WGA pos cells, have not been shown to engraft in allogeneic recipients. 23, 24 In contrast, in a syngeneic setting, it has been shown that very low numbers of purified stem cells can be used for the complete reconstitution of lethally irradiated recipients. 17, 18, 24 Current data as well as previous studies 5, 13, 25 indicate that successful induction of transplantation tolerance depends on the number of stem cells injected, the dose of TBI used and the antigenic disparity between donor and recipient.
The present experiments show that allogeneic skin transplantation can be performed successfully directly following as well as 7 weeks after sublethal conditioning and injection of donor-specific fetal liver or c-kit + cells. Also, second donor-type grafts, transplanted 4 months after the first, were permanently accepted by mixed chimeras. All chimeric animals always rejected unrelated third party skin grafts and showed, in vitro, CTL reactivity to third party target cells. Thus, tolerant mice are immunocompetent and the tolerance is really donor-specific.
Previously, we were able to show, that by administration of a mixture of donor and host bone marrow, the level of chimerism can be manipulated. In this way, we are able to maintain as many host-derived antigen presenting cells as possible, necessary for an optimal functioning host immune system. 13 It has been reported that mixed chimerism is associated with protection against acute GVHD. 26 We propose that autologous G-CSF-mobilized peripheral blood stem cells can be used as an alternative for host-derived bone marrow cells in the clinical situation. These autologous cells could be collected at any time while a patient is on the transplantation waiting list and cryopreserved until the day of transplantation.
How does chimerism play a role in the induction of donor-specific tolerance? Intrathymic deletion of potentially host and donor-reactive T cells has been suggested as an important mechanism for specific tolerance induction in mixed chimeras. As has been recently demonstrated by Colson et al 27 negative selection of potentially donorreactive T cells, as assessed by relative T cell receptor (TCR)-V␤ expression, is associated with the presence of donor class II + cells in the thymus. In this situation, the same mechanism(s) could be responsible for the tolerance to self and donor antigens. Because of the self-renewing capacity of stem cells, supply of donor-derived antigen presenting cells is life-long, and so is the chimerism as well as the tolerance. In permanent mixed chimeras we always observe mutual tolerance both in vivo as indefinite acceptance of donor-and host-originated skin grafts, and in vitro, even after FACS sorting of donor-and host-type cells (data not shown). It can be envisaged that further modulation of the T cell repertoire occurs in the periphery. Burlingham 28 described recently a potent 'veto' cell population in the blood of a tolerant human kidney recipient. In addition, mechanisms like clonal anergy and apoptosis following reexposure to antigen in the periphery 29 cannot be excluded. The changes occurring at the molecular level and how such changes relate to T cell nonresponsiveness are still not elucidated and remain central research issues in transplantation immunology.
In our murine skin transplantation model a stable level of chimerism is needed for induction of permanent donor skin graft survival. The degree of chimerism required to induce tolerance could vary for different organs. 30 Experimentally, skin is one of the most difficult tissues to transplant because of its high immunogenicity. Quantitative analysis of chimerism and donor-specific tolerance after several organ transplantations either in the experimental or the clinical setting should help us further in the elucidation of the mechanism and the clinical significance of stem cell chimerism with regard to donor-specific tolerance.
We suggest that our findings might lead to the development of a well-tolerated and nonlethal protocol for donorspecific tolerance induction in clinical organ transplantation that opens the possibility of cessation of long-term immunosuppression in transplant patients.
